



Zelira Appointed to the Board of Directors of the United States National Cannabis Roundtable

11 February 2021

- **Zelira appointed to the Board of Directors of the National Cannabis Roundtable (NCR) in Washington DC USA.**
- **Zelira will join with other key opinion leaders on the Roundtable to drive cannabis policy reform at the federal level in the United States.**
- **NCR welcomes Zelira's commitment to the development of clinically validated break through therapeutics.**

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to be appointed to the Board of Directors of the National Cannabis Roundtable (NCR) (<https://nationalcannabisroundtable.org/>). Zelira will be represented on the NCR board by the CEO USA, Oludare Odumosu, MPH, Ph.D. The NCR is a non-partisan advocacy group focusing on federal cannabis reform in the United States (US). As part of its reform agenda, it is seeking to remove federal restrictions that prohibit medical research involving cannabis and to allow companies to operate legally in the US-based cannabis industry. The Honorary Chairman of the NCR is John Boehner, the former Speaker of The United States Congress. In addition, the Roundtable announced the appointment of a new honorary co-chair, Kathleen Sebelius, who is the former Governor of Kansas and former Human Services Secretary, under President Obama.

Kim Rivers, CEO of Trulieve and Second Vice Chair of the NCR Board of Directors said: "We are excited to have Zelira join our growing Roundtable. Their focus on research and health is groundbreaking and will help us really show the breadth and potential of the cannabis industry".

Dr. Oludare Odumosu said: "The manner that the federal government handles reform will have fundamental impacts on the people we serve. Our company is committed to bringing break-through therapeutics to market and we need to have the regulatory framework that will allow the research to expand and grow on a Federal/National level.

NCR First Vice Chair Chanda Macias said, "I have worked extensively with Dr Odumosu and his colleagues at Zelira Therapeutics. I am personally thrilled that he will be joining us at the table in Washington. His biopharmaceutical expertise will be invaluable as my colleagues and I work to expand access to clinically proven cannabis medicines for patients around the country while also addressing important issues of reform at the federal level."

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

Oludare Odumosu
Managing Director USA

About Zelira Therapeutics (www.zeliratx.com)

About Zelira Therapeutics (www.zeliratx.com) Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of pipeline candidate products undergoing clinical development and proprietary revenue generating products and that were launched into the global markets in 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions. The Company is undertaking product development programs targeting specific conditions (e.g. HOPE™) and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain. The Company conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States. The Company has developed two proprietary formulations (HOPE™) already launched and generating revenues in Pennsylvania and Louisiana, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products.

About National Cannabis Roundtable (www.nationalcannabisroundtable.org)

The National Cannabis Roundtable promotes common sense federal regulation, tax equality and financial services reform and supports changing federal law to acknowledge states' rights to regulate and manage cannabis policy. The membership of the National Cannabis Roundtable represents every aspect of the cannabis supply chain-members operate in 23 states with legal cannabis programs, including the District of Columbia including growers, processors, retailers, wellness centers, investors, entrepreneurs, and publicly traded companies. .

Address

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Australia Contacts:

Dr Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com
Level 26, 140 St Georges Terrace
Perth WA 6000
AUSTRALIA

U.S. Contacts:

Dr Oludare Odumosu
Managing Director & CEO, USA
+1 909 855 0675
oodumosu@zeliratx.com
3553 West Chester Pike #110
Newtown Square PA 19073
UNITED STATES OF AMERICA

Tickers

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

GVM Communications, Inc.

Gia Morón
+1 347 678 8079
gia@gvmcommsinc.com